Year: 2024
Type: article
Abstract: placebo group over the first 12 weeks, with headache and fatigue more common in women receiving elinzanetant."Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate to severe [vasomotor symptoms], " authors of the studies wrote.[
DOI: 10.1002/pu.31268
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405736274